SciTegic Launches ISV Partner Program and First Five Members Join

    Business Editors/Health/Medical Writers
    BIOWIRE2K

    SAN DIEGO--(BUSINESS WIRE)--March 8, 2005--SciTegic, Inc., a wholly owned subsidiary of Accelrys, Inc. (NASDAQ:ACCL), announced today a strategic partner program to expand the applications offered on Pipeline Pilot, the leading data pipelining environment in discovery informatics. By helping independent software vendors (ISV) make their scientific applications available on Pipeline Pilot, the program positions Pipeline Pilot as the open standard for life sciences interoperability.
    "Pharmaceutical and biotechnology companies employ software tools from many different vendors. SciTegic is opening up its framework to these ISVs so they can make their applications available to our established user base," commented Matt Hahn, vice president & general manager of SciTegic. "By providing customers with access to a wider range of technologies, Pipeline Pilot will allow its users to further streamline and integrate the tools they use every day."
    Five scientific software companies have already signed up as members of the program: Equbits, Molecular Networks, Virtual Chemistry, ChemNavigator and Barnard Chemistry.
    "We are pleased to join SciTegic's ISV Program so we can provide integrated cheminformatics applications to our customers," said Jean-Pierre Kocher, CEO of Molecular Networks. "This new alliance will give our joint customers a comprehensive integration solution that substantially increases research and development efficiencies."
    "Integration of our 3DPL virtual screening technology with Pipeline Pilot will allow computational scientists to easily build and deploy 3D virtual screens used in library analysis and compound selection," said Scott Hutton, CEO of ChemNavigator. "Using Pipeline Pilot, scientists can easily share and reuse these screens."
    "Initially we are making our clustering and fingerprint generation technologies available as web services within Pipeline Pilot. This will make the tools much more accessible to end users," says founder-Director John Barnard.

    About SciTegic

    SciTegic, a wholly owned subsidiary of Accelrys, Inc. (NASDAQ:ACCL), develops and markets informatics software to the pharmaceutical and biotechnology industries. The company has pioneered a technology approach called "Data Pipelining" to process drug discovery data with unprecedented flexibility. This methodology has established its utility by accelerating informatics research for thousands of users at hundreds of customer sites worldwide. Further information about SciTegic is available at: www.scitegic.com.

    About Molecular Networks

    Molecular Networks (http://www.mol-net.com/) is a provider of molecular modeling and cheminformatics tools.

    About ChemNavigator

    ChemNavigator (http://www.chemnavigator.com/) develops cheminformatics databases and software technology for drug discovery.

    About Barnard Chemical Information

    Barnard Chemical Information (http://www.bci.gb.com/) specializes in cheminformatics software, producing fingerprint, clustering, and Markush-based combinatorial library analysis software.

    About Equbits

    Equbits (http://www.equbits.com/) provides predictive modeling software designed for accuracy, automation, and interpretability. Equbits applies advanced machine learning techniques including Support Vector Machines to QSAR predictive modeling in an easy to use, intuitive software application geared towards HTS and ADME chemists.

    About Virtual Chemistry

    Virtual Chemistry (http://www.virtualchemistry.com/) provides innovative informatics software and services for the pharmaceutical and biotechnology industries.

    This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). When used anywhere in this document, the words "expects," "believes," "anticipates," "estimates," and similar expressions are intended to identify forward-looking statements. Examples of such forward-looking statements herein include statements regarding the future success of the SciTegic ISV Program. Accelrys and SciTegic have based these forward-looking statements on current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Accelrys' strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys claims the protection of the safe harbor for forward-looking statements contained in the Act and, disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

--30--RJ/la*

CONTACT: Accelrys Ian Clements, (858) 799-5440 iclements@accelrys.com or SciTegic Marty Kleine, (858) 279-8800 x214 mkleine@scitegic.com

KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY SOFTWARE SOURCE: Accelrys, Inc.

Copyright Business Wire 2005